PE20131085A1 - Un nuevo conjugado de granulocito colonia-estimulante factor (g-csf) con polietileno glicol - Google Patents

Un nuevo conjugado de granulocito colonia-estimulante factor (g-csf) con polietileno glicol

Info

Publication number
PE20131085A1
PE20131085A1 PE2013000083A PE2013000083A PE20131085A1 PE 20131085 A1 PE20131085 A1 PE 20131085A1 PE 2013000083 A PE2013000083 A PE 2013000083A PE 2013000083 A PE2013000083 A PE 2013000083A PE 20131085 A1 PE20131085 A1 PE 20131085A1
Authority
PE
Peru
Prior art keywords
csf
stimulating factor
cologne
granulocyte
polyethylene glycol
Prior art date
Application number
PE2013000083A
Other languages
English (en)
Inventor
Tatyana Veniaminovna Chernovskaya
Lev Alexandrovich Denisov
Elena Georgievna Rudenko
Dmitriy Valentinovich Morozov
Original Assignee
Biocad Cjsc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45567857&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20131085(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biocad Cjsc filed Critical Biocad Cjsc
Publication of PE20131085A1 publication Critical patent/PE20131085A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

REFERIDA A UN FACTOR ESTIMULANTE DE COLONIA DE GRANULOCITOS (G-CSF) CONJUGADO CON UN MONOMETOXIPOLIETILENGLICOL DE FORMULA (I), DONDE n ES UN ENTERO DE 681 A 1000; m ES UN ENTERO MAYOR O IGUAL A 4; N(ALFA)H-G-CSF ES UN POLIPEPTIDO NATURAL O RECOMBINANTE. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA. DICHO CONJUGADO ES UTIL EN EL TRATAMIENTO DE LEUCOPENIA, NEUTROPENIA EN PACIENTES CON QUIMIOTERAPIA MIELOSUPRESIVA, PACIENTES CON NEUTROPENIA CRONICA, ENTRE OTROS
PE2013000083A 2010-08-13 2011-07-19 Un nuevo conjugado de granulocito colonia-estimulante factor (g-csf) con polietileno glicol PE20131085A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2010133875/10A RU2446173C1 (ru) 2010-08-13 2010-08-13 Новый функционально активный, высокоочищенный стабильный конъюгат гранулоцитарного колониестимулирующего фактора (г-ксф) с полиэтиленгликолем с пролонгированным биологическим действием, пригодный для медицинского применения, и иммунобиологическое средство на его основе

Publications (1)

Publication Number Publication Date
PE20131085A1 true PE20131085A1 (es) 2013-10-10

Family

ID=45567857

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2013000083A PE20131085A1 (es) 2010-08-13 2011-07-19 Un nuevo conjugado de granulocito colonia-estimulante factor (g-csf) con polietileno glicol

Country Status (17)

Country Link
KR (1) KR101549457B1 (es)
CN (1) CN103140499B (es)
CL (1) CL2013000400A1 (es)
CO (1) CO6670557A2 (es)
CR (1) CR20130020A (es)
CU (1) CU24139B1 (es)
DO (1) DOP2013000003A (es)
EA (1) EA019043B1 (es)
EC (1) ECSP13012399A (es)
MA (1) MA34525B1 (es)
MY (1) MY160732A (es)
NI (1) NI201300007A (es)
PE (1) PE20131085A1 (es)
RS (1) RS20130094A1 (es)
RU (1) RU2446173C1 (es)
SG (1) SG187572A1 (es)
WO (1) WO2012021088A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012110057A1 (en) 2011-02-15 2012-08-23 Chemisches Institut Schaefer Ag Cefuroxime safety kit
WO2013185105A1 (en) 2012-06-07 2013-12-12 Children's Hospital Los Angeles Methods for treating neutropenia using retinoid agonists
CN103908427B (zh) * 2013-01-05 2014-12-17 石药集团百克(山东)生物制药有限公司 一种聚乙二醇修饰的rhG-CSF注射液及其制备方法
RU2535002C2 (ru) * 2013-04-04 2014-12-10 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт фармакологии" Сибирского отделения Российской академии медицинских наук Средство коррекции отдаленных последствий нарушений сперматогенеза, вызванных цитостатическим воздействием
CN106413701A (zh) 2014-02-18 2017-02-15 洛杉矶儿童医院 用于治疗中性粒细胞减少症的组合物和方法
EA035448B1 (ru) * 2014-07-14 2020-06-17 Геннова Биофармасьютикалз Лимитед СПОСОБ ОЧИСТКИ рчГ-КСФ
IL247369B (en) * 2016-08-18 2018-08-30 B G Negev Tech And Applications Ltd Polypeptides derived from CSF-m and their uses
KR102020995B1 (ko) * 2017-10-30 2019-09-16 한국코러스 주식회사 콜로니자극인자와 폴리올이 접합된 접합물을 고수율로 제조하는 방법
CN115297844A (zh) * 2020-03-17 2022-11-04 德拉格雷丘尔公司 用于吸入的gm-csf的液体制剂

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2006596C (en) * 1988-12-22 2000-09-05 Rika Ishikawa Chemically-modified g-csf
US5252714A (en) * 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
KR20040083268A (ko) * 2003-03-21 2004-10-01 한미약품 주식회사 안정성이 증가된 인간 과립구 콜로니 자극인자 융합체 및이의 제조방법
RU2278870C2 (ru) * 2004-08-30 2006-06-27 Закрытое Акционерное Общество "Биокад" Способ получения, выделения, очистки и стабилизации рекомбинантного гранулоцитарного колониестимулирующего фактора человека, пригодного для медицинского применения, и иммунобиологическое средство на его основе
US20070196416A1 (en) * 2006-01-18 2007-08-23 Quest Pharmaceutical Services Pharmaceutical compositions with enhanced stability
US8840882B2 (en) * 2006-06-23 2014-09-23 Quintessence Biosciences, Inc. Modified ribonucleases

Also Published As

Publication number Publication date
CU20130012A7 (es) 2013-04-19
EA201101035A1 (ru) 2012-02-28
CU24139B1 (es) 2015-12-23
KR20130043167A (ko) 2013-04-29
DOP2013000003A (es) 2013-07-31
WO2012021088A1 (en) 2012-02-16
ECSP13012399A (es) 2013-05-31
KR101549457B1 (ko) 2015-09-02
CN103140499B (zh) 2014-12-17
MA34525B1 (fr) 2013-09-02
CO6670557A2 (es) 2013-05-15
MY160732A (en) 2017-03-15
EA019043B1 (ru) 2013-12-30
SG187572A1 (en) 2013-03-28
CL2013000400A1 (es) 2013-07-26
CN103140499A (zh) 2013-06-05
RS20130094A1 (en) 2013-08-30
RU2446173C1 (ru) 2012-03-27
NI201300007A (es) 2014-05-26
CR20130020A (es) 2013-02-20

Similar Documents

Publication Publication Date Title
PE20131085A1 (es) Un nuevo conjugado de granulocito colonia-estimulante factor (g-csf) con polietileno glicol
ES2619309T3 (es) Ácido hialurónico sulfatado para el tratamiento de la osteoartritis degenerativa
PE20140382A1 (es) Polipeptidos derivados de la il-2 con actividad agonista para la terapia del cancer e infecciones cronicas
CO6680667A2 (es) Derivados ester de ácido borónico cíclico y sus usos terapéuticos
BR112018004536A2 (pt) peptídeos de endereçamento à cartilagem
CL2013000018A1 (es) Compuestos derivados de indolizina , su procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento del cancer, entre otros.
BR112012016853A2 (pt) "composições farmacêuticas para administração oral de peptídeos de insulina".
NZ594056A (en) New stable formulations of recombinant human albumin-human granulocyte colony stimulating factor fusion protein
NZ599792A (en) Immunomodulatory polypeptides derived from il- 2 and their use thereof in the therapeutic of cancer and chronic infections
MY163215A (en) Thermogelling anaesthetic compositions
MY160922A (en) Polyethylene glycol conjugated blood coagulation factor vii
EA201370006A1 (ru) Местная фармацевтическая композиция, содержащая флурбипрофен
IN2014DN00277A (es)
PE20150288A1 (es) Dialisato a base de polimero
EA201290941A1 (ru) КОНЪЮГИРОВАННЫЙ ФАКТОР СВЕРТЫВАНИЯ КРОВИ VIIa
CL2011001427A1 (es) Compuestos derivados de 4-azetidinil-1-heteroaril-ciclohexanol; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como epoc, aterosclerosis, artritis reumatoide, entre otras.
IN2014DN08598A (es)
EA201300539A1 (ru) Твердая композиция для приема внутрь (варианты), способ терапевтической или нетерапевтической профилактики желудочно-кишечных расстройств или поддержания здорового состояния желудочно-кишечного тракта с ее помощью (варианты) и упаковка, ее содержащая
PE20142325A1 (es) Composiciones derivadas de la quitosana
PE20081881A1 (es) Agentes terapeuticos para canceres resistentes a agentes quimioterapicos que incluyen como ingrediente activo un anticuerpo que reconoce hla de clase i y sus usos
MX2015013263A (es) Conjugados de hemoglobina oxido de polialquileno valerato.
BR112015022730A2 (pt) formulações de rfviii, método para conjugação covalente de rfviii com um polímero biocompatível e uso de rfviii no preparo de formulação de rfviii para tratamento de hemofilia a
BR112013006651A2 (pt) composição e cocristal de aprepitante l-prolina
PH12015500807A1 (en) Tgf�-derived polypeptides and uses thereof
MX2016004660A (es) Composiciones de peptido novedosas.

Legal Events

Date Code Title Description
FC Refusal